

Drug Utilization Review (DUR) Meeting Minutes December 5, 2011

Members Present: Norman Byers, John Savageau, Russ Sobotta, Cheryl Huber, Greg Pfister, Patricia Churchill, Carrie Sorenson, Leann Ness, Jeffrey Hostetter

Members Absent: Kim Krohn, David Clinkenbeard, Steve Irsfeld, James Carlson, Todd Twogood, Carlotta McCleary

Medicaid Pharmacy Department: Brendan Joyce, Gary Betting

HID Staff Present: Candace Rieth

Chair, G. Pfister called the meeting to order at 1:00 pm. Chair, G. Pfister asked for a motion to approve the minutes from the September meeting. N. Byers moved that the minutes be approved and C. Huber seconded the motion. Chair, G. Pfister called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update

B. Joyce informed the board members that there has been no budget updates from fiscal since the last DUR Board meeting.

Dificid Second Review

A motion and second were made at the September meeting to place Dificid on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Hereditary Angioedema Second Review

A motion and second were made at the September meeting to place agents used to treat hereditary angioedema on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Oral Anticoagulants Second Review

A motion and second were made at the September meeting to place Pradaxa on prior authorization. The topic was brought up for a second review. J. Savageau made a motion to add Xarelto to the prior authorization. N. Byers seconded the motion. J. Robinson, representing Boehringer Ingelheim, spoke regarding Pradaxa. J. Stoffel, representing Janssen Scientific Affairs, spoke regarding Xarelto. Chair, G. Pfister called for a voice vote to approve the amendment. The motion passed with no audible dissent. Chair, G. Pfister called for a voice vote to approve the amended original motion. The motion passed with no audible dissent.

Yearly PA Review

The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Solodyn, Oracea, Oxycontin, Short-Acting Beta₂ Agonists, Soma 250, Vusion, Targeted Immunomodulators, Moxatag, Uloric, Smoking Cessation, Topical Anesthetic Agents, Name Brand Narcotics, Ribapak, Metozolv, Suboxone/Subutex, Ampyra, Ultram/Rybix/Ryzolt, and Xolair. No changes were made.

Pulmonary Arterial Hypertension Agents Review

B. Joyce reviewed PAH information with the Board. W. Braden, representing United Therapeutics, spoke regarding Adcirca and Tyvaso. P. Miner, representing Gilead, spoke regarding Letairis. After discussion, N. Byers made a motion to place agents used to treat PAH on

prior authorization. J. Hostetter seconded the motion. This topic will be brought up at the next meeting for finalization.

Topical Acne Agents Review

B. Joyce reviewed topical acne agents information with the Board. There was no public comment. After discussion, N. Byers made a motion to place an age restriction on topical acne agents for patients less than 10 and greater than 35 to have a dermatologist involved in therapy. G. Pfister seconded the motion. J. Hostetter made a motion to place topical acne agents on prior authorization. C. Sorenson seconded the motion. This topic will be brought up at the next meeting for finalization.

Benign Prostatic Hyperplasia Review

B. Joyce reviewed BPH information with the Board. There was no public comment. After discussion, G. Pfister made a motion to place BPH agents on prior authorization. N. Byers seconded the motion. This topic will be brought up at the next meeting for finalization.

Juvisync Review

B. Joyce reviewed Juvisync with the Board. S. Carlson, representing Merck, spoke regarding Juvisync. After discussion, J. Hostetter made a motion to place combination products that are more expensive than their individual components, such as Juvisync, on prior authorization. G. Pfister seconded the motion. This topic will be brought up at the next meeting for finalization.

Gralise Review

B. Joyce reviewed Gralise with the Board. There was no public comment. N. Byers made a motion to place Gralise on prior authorization, with failure of gabapentin. G. Pfister seconded the motion. This topic will be brought up at the next meeting for finalization.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. P. Churchill moved to approve the new criteria and J. Savageau seconded the motion. Chair, G. Pfister called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held March 5, 2012. P. Churchill made a motion to adjourn the meeting. N. Byers seconded. The motion passed with no audible dissent. Chair G. Pfister adjourned the meeting at 2:25 pm.